Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Revilla Lopez (Barcelona, Spain), C. Berastegui (Barcelona, Spain), B. Saez (Barcelona, Spain), A. Mendez (Barcelona, Spain), M. Lopez Meseguer (Barcelona, Spain), I. Sansano (Barcelona, Spain), S. Gomez Olles (Barcelona, Spain), A. Roman (Barcelona, Spain). Long-term sirolimus treatment in lymphangioleiomyomatosis. 3687

Member's Comments

No comment yet.

Related content which might interest you: Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Doxycicline in the treatment of lymphangioleiomyomatosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM) Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients Source: Eur Respir Rev 2013; 22: 93-95 Year: 2013 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Long-term sitaxsentan therapy in PAH Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Early sirolimus immunosuppression is safe in lung transplantation Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020 Year: 2021 Outcome of two patients with lymphangioleiomyomatosis without anti-estrogen therapy Source: Eur Respir J 2006; 28: Suppl. 50, 96s Year: 2006 Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC) Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003 Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Combination therapy may be beneficial for the treatment of lymphangioleiomyomatosis Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Combination of pentoxifylline and steroids in sarcoidosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 269s Year: 2005 Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004 Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. A retrospective study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016